Organon & Co. (OGN)
| Market Cap | 7.48B |
| Revenue (ttm) | 8.10B |
| Net Income (ttm) | n/a |
| Shares Out | 253.52M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 22 |
| Last Price | $29.53 |
| Previous Close | $29.41 |
| Change ($) | 0.12 |
| Change (%) | 0.41% |
| Day's Open | 29.25 |
| Day's Range | 28.85 - 29.87 |
| Day's Volume | 4,218,326 |
| 52-Week Range | 27.25 - 38.75 |
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon Announces Filing of Form 10-Q for the quarter ended March 31, 2021
Although spinoffs of well-known organizations have been known to outperform, you'll want to examine OGN stock carefully. The post Motivation Really Matters When It Comes to Organon appeared first on Inv...
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon, A Global Women's Healthcare Company, Completes Acquisition of Alydia Health - A Medical Device Company Focused on Postpartum Hemorrhage
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Multimedia news release announcing the launch of Organon, a global healthcare company formed through a spinoff from Merck.
LONDON--(BUSINESS WIRE)--Organon (NYSE: OGN) has today launched as the only global health company of its size, with a singular vision: to make a better and healthier every day for every woman. With a ma...
JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Multimedia news release announcing the launch of Organon, a global healthcare company formed through a spinoff from Merck.
NEW YORK, May 27, 2021 /PRNewswire/ -- Organon & Co. (NYSE: OGN) will be added to the S&P 500 prior to the open of trading on Thursday, June 3, replacing HollyFrontier, which will be removed from the S&...
About OGN
Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio in the United States, Ca... [Read more...]
| Industry Drug Manufacturers-General | Founded 1923 |
| Stock Exchange NYSE | Ticker Symbol OGN |
Financial Performance
In 2020, Organon's revenue was $8.10 billion, a decrease of -15.05% compared to the previous year's $9.53 billion. Earnings were $2.16 billion, a decrease of -32.88%.